Company · Edinburgh

Targopep

Targopep is a life sciences company based in Edinburgh, incorporated in Scotland in 2021 (SC715354).

What they do

“Delivering the Future of Oligonucleotide Therapies TargoPep uses its next-generation platform to design, research and refine targeted neurological delivery solutions for oligonucleotide therapeutics.”

In its own words, on targopep.com

In plain speak

They design and develop delivery systems to get oligonucleotide medicines into the brain and nervous system.

Ayeoh Overview

Targopep is a life sciences organisation based in Edinburgh. (ayeoh's record) It was incorporated in Scotland on 18 Nov 2021 as company SC715354. (Companies House) Its website says: “Delivering the Future of Oligonucleotide Therapies TargoPep uses its next-generation platform to design, research and refine targeted neurological delivery solutions for oligonucleotide therapeutics.” (targopep.com)

Companies House lists 4 active officers, among them Fergus Stewart, Dr McWhinnie (director, since Nov 2021), Glenn, Prof Burley (director, since Nov 2021) and Kenneth Hall Fyvie (director, since Nov 2021). (Companies House, profile card) Its own website's latest post is “Global investment in gene therapeutics is on the rise, but are these investments on a sound footing?”, from 14 May 2024. (Latest from Targopep, the post)

Latest from Targopep

Global investment in gene therapeutics is on the rise, but are these investments on a sound footing?

14 May 2024, from targopep.com, posted by the company

Scottish EDGE – finalist

23 Apr 2024, from targopep.com, posted by the company

How ‘Delivery Enabled’ oligotherapeutics can change the landscape of disease and treatment

29 Feb 2024, from targopep.com, posted by the company

TargoPep enhances the successes of ‘Cell Penetrating Peptides’ to develop ‘Advanced Delivery Peptides’. But why did we do this?

30 Jan 2024, from targopep.com, posted by the company

TargoPep presents at TIDES Europe

1 Nov 2023, from targopep.com, posted by the company

Timeline

14 May 2024from the companyGlobal investment in gene therapeutics is on the rise, but are these investments on a sound footing?
23 Apr 2024from the companyScottish EDGE – finalist
29 Feb 2024from the companyHow ‘Delivery Enabled’ oligotherapeutics can change the landscape of disease and treatment
30 Jan 2024from the companyTargoPep enhances the successes of ‘Cell Penetrating Peptides’ to develop ‘Advanced Delivery Peptides’. But why did we do this?
1 Nov 2023from the companyTargoPep presents at TIDES Europe
18 Nov 2021directorFergus Stewart, Dr McWhinnie appointed Director
18 Nov 2021directorGlenn, Prof Burley appointed Director
18 Nov 2021directorKenneth Hall Fyvie appointed Director
18 Nov 2021directorSimon Paul, Prof Mackay appointed Director
18 Nov 2021incorporatedTargopep incorporated as SC715354

Register facts, funding, grants and the latest news, each linked or sourced. The data file holds the register facts, funding and grants only.

Use this data

Download everything ayeoh holds on Targopep, free: CSV · JSON-LD. Every row carries its source and date.

Record completeness 48 of 100; not yet held: logo, filed accounts, three years of accounts, turnover.

Licence: free to read and cite with a link to ayeoh.io; bulk, API or commercial reuse needs an ayeoh licence. Cite as: ayeoh.io, “Targopep”, ayeoh.io/c/targopep, accessed 8 Nov 2026.